Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MRT-2359 |
Synonyms | |
Therapy Description |
MRT-2359 is a small molecule that induces CRBN-dependent proteasomal degradation of GSPT1, potentially leading to decreased tumor cell proliferation and reduced tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3929). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MRT-2359 | MRT 2359|MRT2359 | MRT-2359 is a small molecule that induces CRBN-dependent proteasomal degradation of GSPT1, potentially leading to decreased tumor cell proliferation and reduced tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3929). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05546268 | Phase Ib/II | MRT-2359 | Study of Oral MRT-2359 in Selected Cancer Patients | Recruiting | USA | CAN | 0 |